LONDON, Feb. 28, 2012 /PRNewswire/ -- Based on its recent analysis of the neuro-psychiatric devices market, Frost & Sullivan recognises Brainsway with the 2012 Global Frost & Sullivan New Product Innovation Award. Brainsway’s cutting-edge deep Transcranial Magnetic Stimulation (dTMS) is the only non-invasive technique that can be used for the treatment of depression and other neuro-psychiatric disorders without causing any significant side effects.
“The system has shown high efficacy compared to conventional treatment methods for depression and also the standard TMS systems that are currently used in the market,” notes Frost & Sullivan Research Analyst Brahadeesh Chandrasekaran. “Opinion leaders across Europe and the United States are already using this device and the clinical evidence so far suggests that Brainsway’s dTMS is highly efficient and extremely promising for the treatment of neuro-psychiatric disorders.”
There are a few other TMS devices in the market that can activate brain surface cells. Brainsway’s deep TMS, however, is the only device that can activate brain cells in deeper regions.
“The device has obtained the CE mark for treating depression, bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD) and Parkinson’s disease,” says Chandrasekaran. “It is on the last stretch of a multi-centre trial for obtaining FDA approval for treating depression and has received an IDE for starting another multi-centre trial in bipolar disorder patients.”
In conventional treatment methods (both drug therapy and electro-convulsive therapy), patients are prone to high risk of side effects. In comparison, Brainsway’s dTMS system is the only TMS system that allows direct, non-invasive activation of deep brain cells.
Its unique magnetic coil design produces the magnetic pulses required to activate the deeper brain structures without causing any side effects, eliminating the need for anaesthesia and hospitalisation.
Potential clinical applications in more than 10 to 15 different types of neuro-psychiatric disorders, coupled with the benefits offered to both patients and medical professionals, are set to ensure the widespread acceptance of Brainsway’s dTMS.
Frost & Sullivan presents this award to the company that has demonstrated excellence in developing a product with innovative elements that leverages leading edge technologies, that offers valued added features and benefits, supports increased customer ROI and has the potential for enhanced customer acquisition/penetration.
Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Brainsway Ltd.
Brainsway Ltd. is dedicated to the development and marketing of Deep TMS (Transcranial Magnetic Stimluation) systems - novel, noninvasive medical devices for treatment of a wide range of neurological and psychopathological disorders. In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method. Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson’s disease, Alzheimer’s disease, autism and post-traumatic stress disorder.
Our initial focus is the treatment of major depression. The unique technology of Brainsway is based on patents filed by the U.S. National Institute of Health (NIH) and by the company. Brainsway has an exclusive license from the NIH for the patent and technology. Headquartered in Jerusalem, Israel, the company’s ordinary shares and warrants trade on the Tel Aviv Stock Exchange under the symbol ‘BRIN’.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company’s Growth Partnership Service provides the CEO and the CEO’s Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Contact:
Catherine Brassell
Best Practices
Frost & Sullivan
catherine.brassell@frost.com
P: +27(0)21 680 3267
www.frost.com
SOURCE Frost & Sullivan
